BioVie (BIVI) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioVie (BIVI) has outperformed Palatin Technologies (PTN) over the past year, losing 38.2% versus a loss of 79.9%. Over five years, PTN leads with a -99.3% price change compared with -99.9% for BIVI. BioVie is the larger company by market cap ($8.6 million vs $8.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | PTN |
|---|---|---|
| Share price | $0.80 | $4.58 |
| Market cap | $8.58M | $8.16M |
| 1-day change | -12.07% | -7.10% |
| YTD return | -31.03% | -70.22% |
| 1-year return | -38.22% | -79.93% |
| 5-year return | -99.87% | -99.35% |
| EPS (TTM) | $-2.85 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.83M |
| Net income (latest FY) | $-22.07M | $-8.38M |
| Operating margin | — | -98.17% |
| Net margin | — | -94.88% |
| 52-week high | $3.79 | $31.00 |
| 52-week low | $0.7515 | $4.51 |
| Distance from 52-week high | -78.89% | -85.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +557.50% | +1068.12% |
| Average volume | 568.61K | 71.93K |
| Shares outstanding | 10.72M | 1.78M |
| Employees | 13 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed PTN by 41.7 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
BIVI vs PTN FAQ
Which is bigger, BioVie or Palatin Technologies?
BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.16M for Palatin Technologies (PTN).
Which stock has performed better over the past year, BIVI or PTN?
BIVI returned -38.22% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.